Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups

References

• Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP, Dou QP. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res 2008; 18:7283-92; PMID:18794115; http://dx.doi.org/10.1158/0008-5472.CAN-07-6246
   PubMed Web of Science ®Google Scholar
• Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 2005; 5:700-13; PMID:16023083; http://dx.doi.org/10.1016/j.bcp.2005.04.043
   PubMed Web of Science ®Google Scholar
• Bharti AC, Shishodia S, Reuben J, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB. Nuclear factor-kB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004; 103:3175-84; PMID:15070700; http://dx.doi.org/10.1182/blood-2003-06-2151
   PubMed Web of Science ®Google Scholar
• Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human myeloma cells. J Immunol 2003; 171:3863-71; PMID:14500688; http://dx.doi.org/10.4049/jimmunol.171.7.3863
   PubMed Web of Science ®Google Scholar
• Park J, Ayyappan V, Bae EK, Lee C, Kim BS, Kim BK, Lee YY, Ahn KS, Yoon SS. Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. Mol Oncol 2008; 2:317-26; PMID:19383353; http://dx.doi.org/10.1016/j.molonc.2008.09.006
   PubMed Web of Science ®Google Scholar
• Sung B, Kunnumakkara GS, Sethi G, Anand P, Gluha S, Aggarwal BB. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and botezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 2009; 8:959-70; PMID:19372569; http://dx.doi.org/10.1158/1535-7163.MCT-08-0905
   PubMed Web of Science ®Google Scholar
• Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, et al. The molecular classification of multiple myeloma. Blood 2006; 108:2020-28; PMID:16728703; http://dx.doi.org/10.1182/blood-2005-11-013458
   PubMed Web of Science ®Google Scholar
• Chesi M, Bergsagel PL. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol 2013; 97:313-23; PMID:23456262; http://dx.doi.org/10.1007/s12185-013-1291-2
   PubMed Web of Science ®Google Scholar
• Johnson SK, Heuck CJ, Albino AP, Qu P, Zhang Q, Shaughnessy JD Jr. The use of molecular-base risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. Int J Hematol 2011; 94:321-33; PMID:22002477; http://dx.doi.org/10.1007/s12185-011-0948-y
   PubMed Web of Science ®Google Scholar
• Wuillème-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, Harousseau JL, Amiot M, Bataille R. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005; 9:1248-52; PMID:15902294; http://dx.doi.org/10.1038/sj.leu.2403784
   PubMed Web of Science ®Google Scholar
• Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs 2011; 1:59-70; PMID:20812891; http://dx.doi.org/10.1517/14728214.2010.515210
   PubMed Web of Science ®Google Scholar
• Surget S, Chiron D, Gomez-Bougie P, Descamps G, Ménoret E, Bataille R, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C. Cell Death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer Res 2012; 17:4562-73; PMID:22738917; http://dx.doi.org/10.1158/0008-5472.CAN-12-0487
   PubMed Web of Science ®Google Scholar
• Jourdan M, Ferlin M, Legouffe E, Horvathova M, Liautard J, Rossi JF, Wijdenes J, Brochier J, Klein B. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol 1998; 100:637-46; PMID:9531328; http://dx.doi.org/10.1046/j.1365-2141.1998.00623.x
   PubMed Web of Science ®Google Scholar
• Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R, Amiot M. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002; 100:194-99; PMID:12070027; http://dx.doi.org/10.1182/blood.V100.1.194
   PubMed Web of Science ®Google Scholar
• Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maïga S, Avet-Loiseau H, Bataille R, Moreau P, Le Gouill S, et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood 2011; 118: 3901-10; PMID:21835956; http://dx.doi.org/10.1182/blood-2010-11-317438
   PubMed Web of Science ®Google Scholar
• Gomez-Bougie P, Amiot M. Apoptotic machinery diversity in multiple myeloma molecular subtypes. Front Immunol 2013; 4:1-6; PMID:23355837; http://dx.doi.org/10.3389/fimmu.2013.00467
   PubMedGoogle Scholar
• Surget S, Lemieux-Blanchard E, Maïga S, Descamps G, Le Gouill S, Moreau P, Amiot M, Pellat-Deceunynck C. Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. Leuk Lymphoma 2014; Epub ahead of print; PMID:24308434
   PubMed Web of Science ®Google Scholar
• Moreau P, Avet-Loiseau H, Harousseau JL, Attal M. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol 2011; 9:1898-06; PMID:21482979; http://dx.doi.org/10.1200/JCO.2010.32.5878
   PubMed Web of Science ®Google Scholar
• Lodé L, Eveillard M, Trichet V, Soussi T, Wuillème S, Richebourg S, Magrangeas F, Ifrah N, Campion L, Traullé C et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 2010; 95:1973-76; PMID:Can't; http://dx.doi.org/10.3324/haematol.2010.023697
   PubMed Web of Science ®Google Scholar
• Bush JA, Cheung KJ Jr, Li G. Curcumin induces apoptosis in human melanoma cells through a Fas/receptor/caspase-8 pathway independent of p53. Exp Cell Res 2001; 2:305-14; PMID:11716543; http://dx.doi.org/10.1006/excr.2001.5381
   PubMed Web of Science ®Google Scholar
• Golombick T, Diamond TH, Manoharan A, Ramakrishna R. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: A randomized, double-blind placebo controlled cross-over 4g study and an open-label 8g extension study. Am J Hematol 2012; 5:455-60; PMID:11716543 ; http://dx.doi.org/10.1002/ajh.23159
   PubMed Web of Science ®Google Scholar
• Moreaux J, Klein B, Bataille R, Descamps G, Maïga S, Hose D, Goldschmidt H, Jauch A, Rème T, Jourdan M et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 2011; 4:574-82; PMID:21173094; http://dx.doi.org/10.3324/haematol.2010.033456
   PubMed Web of Science ®Google Scholar
• Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 2007; 67:5418-24; PMID:17545623; http://dx.doi.org/10.1158/0008-5472.CAN-06-4322
   PubMed Web of Science ®Google Scholar